Date: 2016-04-28
Type of information: Construction of a production plant
Compound: RNAi therapeutics
Company: Alnylam Therapeutics (USA - MA)
Therapeutic area:
Type agreement: construction of a production plant
Action mechanism: RNAi
Disease:
Details: * On April 28, 2016, Alnylam Pharmaceuticals announced that it will break ground on a state-of-the-art biopharmaceutical manufacturing facility in Norton, Massachusetts . The facility will supply RNAi therapeutics for Alnylam's clinical and commercial needs. Construction on the 200,000 square foot manufacturing facility is expected to complete in 2018 and it will initially employ approximately 150 new full-time employees.
Financial terms:
Latest news:
